Publicaciones en colaboración con investigadores/as de Helsinki University Central Hospital (6)

2021

  1. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

    Blood, Vol. 137, Núm. 9, pp. 1154-1165

2020

  1. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1850-1859

2017

  1. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

    European Journal of Haematology, Vol. 99, Núm. 3, pp. 199-206

2016

  1. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma

    Blood, Vol. 128, Núm. 4, pp. 497-503

2003

  1. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study

    British Journal of Haematology, Vol. 122, Núm. 3, pp. 394-403

2001

  1. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European group for blood and marrow transplantation (EBMT)

    Bone Marrow Transplantation, Vol. 27, Núm. 5, pp. 511-515